Table 2.

Treatment with dupilumab led to normalization of CD4 T cell induction of intracellular IL-17 following stimulation.

Unstimulated	% Positive	Stimulated	% Positive	Reference range (%)
Before treatment
CD4+IL17a+	0	CD4+IL17a+	0.4	≥0.5
After treatment
CD4+IL17a+	0.02	CD4+IL17a+	0.63	≥0.5